Developer docs
API playgroundTry for free, no card

Search company profiles

BrightInsight

Full company profile

uuid00006zk

Namestring
BrightInsight
Legal namestring
BrightInsight, Inc.
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BrightInsight is a regulated digital health platform company serving global biopharma and medtech clients. Founded in 2017-2018 as a spin-off from Flex Ltd. and headquartered in San Jose, California, it operates a cloud-based platform built on Google Cloud that provides infrastructure for patient companion applications, digital patient support programs, and Software as a Medical Device (SaMD) solutions. Its platform is supported by an extensive certification stack — ISO 13485, IEC 62304, ISO/IEC 27001, HITRUST CSF, HIPAA, GDPR, CE Mark, EU MDR, MDSAP, and HDS — enabling compliant deployment across 60+ countries under a built-in Quality Management System. The platform addresses therapy discontinuation and adherence problems that cost the industry an estimated $500B+ annually, with the flagship AI-enabled Patient Persistence Solution detecting behavioral signals that precede therapy drop-off and triggering interventions at clinically meaningful moments. Adjacent solutions include the Connected Diagnostics Platform (for IVD manufacturers such as bioMérieux) and the Disease Management Solution, with customer-facing apps such as MyWay (Sanofi), Hizentra (CSL Behring), Hemgenix, myVisionTrack (Stanford Health Care), and a CE-marked Emicizumab dosing calculator.

BrightInsight monetizes through an enterprise SaaS subscription model (annual contracts) plus professional services for implementation, customization, and consulting. Pricing is quote-based and customized to scope, therapeutic area, geography, and patient population. Go-to-market is exclusively direct enterprise sales targeting senior executives at the world's top biopharma and medtech organizations — including Sanofi, Roche, AstraZeneca, CSL Behring, Novo Nordisk, UCB, Regeneron, and bioMérieux — with marketing amplified through industry events (HLTH, JPM, BIO, HIMSS), content marketing, and an executive Digital Health C-Suite Series. Distribution is anchored on the company's regulatory clearance, demonstrated clinical outcomes (79% retention at 3 months and 71% at 12 months for Hizentra versus a ~45% industry average; 80%+ retention at 12 months for myVisionTrack), and the ability to compress custom builds from 12+ months to roughly 6 months.

The company is venture-backed and private, having raised $179M+ across five disclosed rounds, including a $101M Series C in March 2021 led by General Catalyst at a $750M valuation, and a $13M strategic investment in January 2026 from existing investors to accelerate AI-enabled persistence solutions. It has been recognized on the Deloitte Technology Fast 500 for two consecutive years and as a Frost & Sullivan Global Healthcare IoT Company of the Year. Customer concentration is anchored on a handful of large multi-year pharma partnerships, but the platform is configurable across eight therapeutic areas (cardiovascular, diabetes, gene therapy, immunology, mental health/neurology, oncology/hematology, rare diseases, respiratory), and the 2026 Havas Health global agency partnership signals an effort to broaden commercial reach at the brand level.

Short descriptiontext

BrightInsight provides a regulated cloud-based digital health platform for global biopharma and medtech companies, enabling compliant patient companion apps, Software as a Medical Device (SaMD) solutions, and AI-driven therapy persistence programs deployed across 60+ countries with enterprise customers including Sanofi, CSL Behring, Roche, and AstraZeneca.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regulated digital health platform, patient persistence software, biopharma digital solutions, medical device software, SaMD platform
Industry5 codes
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Health Services8000
Product category
Digital Health Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Platform/SaaS Subscription
TypeSubscription Recurring
Description

Cloud-based platform deployed as managed service with subscription pricing. Provides infrastructure for patient companion apps, digital patient support programs, and SaMD solutions across global markets.

brightinsight.com
2Professional Services
TypeProfessional Services
Description

Implementation, customization, and consulting services to deploy digital health solutions on the BrightInsight Platform.

brightinsight.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Enterprise Platform Subscription
ModelSubscriptionBilling cadenceAnnual
Notes

Custom enterprise pricing based on scope, number of therapeutic areas, geographic deployment requirements, and patient population size. Quote-based engagement model.

brightinsight.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1BrightInsight Platform
Description

The company's core regulated digital health IoT platform for biopharma and medtech companies

brightinsight.com
+6 more records
Core offering1 text field

BrightInsight provides a cloud-based regulated digital health platform for biopharma and medtech companies, offering infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries. Its AI-enabled patient persistence solution predicts and prevents therapy drop-off by detecting behavioral signals and triggering interventions, delivering pre-built regulatory compliance modules (HIPAA, GDPR, ISO 13485, IEC 62304, HITRUST, EU MDR) and configurable tools across multiple therapeutic areas.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 4% lower discontinuation rate and 4% improvement in adherence after one year for Sanofi Patient App users vs. non-users
+5 more records
Product overview1 text field

BrightInsight offers a unified digital health platform architecture with multiple integrated solutions. The core BrightInsight Platform provides cloud-based infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions for biopharma and medtech companies. Built upon this platform are the Patient Persistence Solution (AI-powered therapy adherence), Disease Management Solution, and Connected Diagnostics Platform (for IVD companies). The company delivers specific patient-facing products including the MyWay App (Sanofi partnership), Hizentra App (CSL Behring), Hemgenix Companion App, and myVisionTrack App (Stanford), along with the CE-marked Emicizumab Dosing Calculator. The platform operates across 60+ countries with global regulatory compliance.

Product and service12 records
1BrightInsight Platform
CategoryDigital Health Platform
Description

Cloud-based regulated digital health platform for biopharma and medtech companies providing infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries.

2Patient Persistence Solution
CategoryDigital Health Solution
Description

AI-powered solution that predicts and prevents therapy drop-off by unifying patient experience, detecting behavioral signals preceding discontinuation, and triggering interventions at critical moments to keep patients on therapy longer.

3Connected Diagnostics Platform
CategoryConnected Diagnostics
Description

Digital platform for in vitro diagnostics (IVD) companies that transforms device management from reactive to proactive, featuring workflow portals, analytics dashboards, proxy agent for device-to-cloud communication, and HL7/FHIR integration middleware.

4Disease Management Solution
CategoryDigital Health Solution
Description

Digital solution for biopharma and medtech companies that enhances patient experience and drives value for therapies and devices by supporting the patient journey across care settings.

5MyWay App
CategoryPatient Companion App
Description

Software as Medical Device mobile application providing symptom tracking, medication management, and direct communication with healthcare providers for patients on Sanofi's specialty care medicines.

6Hizentra App
CategoryPatient Companion App
Description

Patient companion app for CSL Behring supporting patients taking Hizentra with medication reminders, record management, infusion tracking, and nurse educator program access; deployed in U.S., Japan, Canada, Chile, and Argentina.

7Patient App (Sanofi)
CategoryPatient Companion App
Description

Digital app developed with Sanofi and Regeneron supporting patients on biologic therapies, demonstrating 4% lower discontinuation rate and improved adherence after one year; adopted by more than 25,000 patients.

8Hemgenix Companion App
CategoryPatient Companion App
Description

Companion application developed in partnership with CSL for Hemgenix gene therapy to support patients undergoing treatment.

9Emicizumab Dosing Calculator
CategoryClinical Decision Support Tool
Description

CE-marked dosing calculator for Emicizumab, a regulated digital health solution built on the BrightInsight Platform.

10myVisionTrack App
CategoryPatient Companion App
Description

Mobile application for macular disease patients developed with Stanford Health Care, showing 80%+ patient retention at 12 months with 83% registered retinal patient engagement.

11Data & Insights Solution
CategoryData Analytics
Description

Solution component providing real-world data capture and actionable insights to help biopharma companies improve patient care and drive measurable business value.

12Software as a Medical Device (SaMD) Solutions
CategoryMedical Device Software
Description

Comprehensive offering for developing, launching, and scaling Software as a Medical Device products including algorithms and clinical decision support tools.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeGTM or Marketing PartnerAnnounced on2026-02-26
Description

Exclusive global strategic partnership designating Havas Health as BrightInsight's single global agency partner for digital patient persistence and adherence solutions. Merges Havas Health's healthcare strategy and patient journey expertise with BrightInsight's compliant digital health platform. Addresses estimated $500B+ annual cost of poor patient adherence.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-12-17
Description

Expanded multi-year partnership (initial 2022) to develop companion applications for Sanofi's specialty care medicines including MyWay mobile app and Patient App for biologic therapies. Demonstrated 4% reduction in discontinuation and 4% adherence improvement. Expansion across international markets and specialty care portfolio.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-05-07
Description

Expanded partnership to enhance patient journey through generative AI. Long-standing technology partner since 2018 launch on Google Cloud Platform. 2018 and 2019 Google Cloud Partner of the Year for Healthcare and Life Sciences.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-09-21
Description

Partnership to launch clinical digital solutions for diagnostics. Connected Diagnostics Platform for clinical decision support.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-03-08
Description

Partnership to build digital care solutions for rare diseases leveraging BrightInsight Platform for compliant digital health solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-25
Description

Global digital health partnership for chronic disease management. BrightInsight IoT platform selected to build and manage digital health solutions within regulatory-compliant environment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-10-23
Description

Connected insulin pens and digital diabetes management solutions using BrightInsight Platform. Long-standing partnership dating to Flex-era origins.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Collaboration with Sanofi on Patient App for key biologic therapy. BrightInsight developed the digital solution supporting patients on therapy with measurable adherence and persistence outcomes.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Enterprise agreement for digital health solutions across brand portfolio. Hizentra app with 25%+ adoption rate, 79% retention at 3 months. Global expansion to Latin America and Canada. Hemgenix companion app for gene therapy.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Digital health initiatives within Roche Personalized Healthcare Division.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Salesforce Health Cloud is a broad CRM/patient engagement platform that biopharma and medtech customers can use for patient companion apps; a broader incumbent that competes for the same enterprise buyer.

TypeDirect peer
Description

Veeva Vault is the dominant regulated SaaS platform for life sciences, including patient engagement and clinical operations. Veeva is the most direct functional comparable to BrightInsight's regulated platform model serving biopharma.

TypeBroad incumbent
Description

IQVIA's eCOA, Patient Cloud and decentralized trial offerings target the same biopharma/medtech buyers with regulated patient-engagement and data-capture software, but as part of a much larger CRO and analytics portfolio.

TypeBroad incumbent
Description

Medidata's Rave eCOA and decentralized clinical trial platform address pharma patient engagement and SaMD-adjacent use cases; competes for the same enterprise budget lines at top biopharma.

TypeDirect peer
Description

Medable provides a regulated, decentralized clinical trial and eCOA platform for biopharma — direct overlap with BrightInsight's SaMD and patient companion app capabilities for clinical and commercial use.

TypeDirect peer
Description

Science 37 operates a decentralized clinical trial platform with connected patient apps and remote data capture, competing for the same biopharma digital engagement and SaMD deployments.

TypeEmerging player
Description

Castor offers a regulated eClinical and connected device data platform for clinical trials — overlapping with BrightInsight's Connected Diagnostics and SaMD modules but at smaller scale and primarily trial-focused.

TypeEmerging player
Description

ObvioHealth provides a decentralized trial and patient engagement app platform aimed at biopharma sponsors, with partial overlap on patient companion apps and adherence.

TypeOthers
Description

Datavant focuses on health-data connectivity and real-world data — adjacent to BrightInsight's Data & Insights module — and could be a partner or competitor in the biopharma RWE layer.

TypeOthers
Description

Redox provides healthcare interoperability APIs; BrightInsight already integrates with HL7/FHIR and partners with Redox-style vendors, making it a comparable ecosystem/data-exchange peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrightInsight

Digital Health Platformbrightinsight.com

BrightInsight provides a regulated cloud-based digital health platform for global biopharma and medtech companies, enabling compliant patient companion apps, Software as a Medical Device (SaMD) solutions, and AI-driven therapy persistence programs deployed across 60+ countries with enterprise customers including Sanofi, CSL Behring, Roche, and AstraZeneca.

What BrightInsight does

BrightInsight is a regulated digital health platform company serving global biopharma and medtech clients. Founded in 2017-2018 as a spin-off from Flex Ltd. and headquartered in San Jose, California, it operates a cloud-based platform built on Google Cloud that provides infrastructure for patient companion applications, digital patient support programs, and Software as a Medical Device (SaMD) solutions. Its platform is supported by an extensive certification stack — ISO 13485, IEC 62304, ISO/IEC 27001, HITRUST CSF, HIPAA, GDPR, CE Mark, EU MDR, MDSAP, and HDS — enabling compliant deployment across 60+ countries under a built-in Quality Management System. The platform addresses therapy discontinuation and adherence problems that cost the industry an estimated $500B+ annually, with the flagship AI-enabled Patient Persistence Solution detecting behavioral signals that precede therapy drop-off and triggering interventions at clinically meaningful moments. Adjacent solutions include the Connected Diagnostics Platform (for IVD manufacturers such as bioMérieux) and the Disease Management Solution, with customer-facing apps such as MyWay (Sanofi), Hizentra (CSL Behring), Hemgenix, myVisionTrack (Stanford Health Care), and a CE-marked Emicizumab dosing calculator.

BrightInsight monetizes through an enterprise SaaS subscription model (annual contracts) plus professional services for implementation, customization, and consulting. Pricing is quote-based and customized to scope, therapeutic area, geography, and patient population. Go-to-market is exclusively direct enterprise sales targeting senior executives at the world's top biopharma and medtech organizations — including Sanofi, Roche, AstraZeneca, CSL Behring, Novo Nordisk, UCB, Regeneron, and bioMérieux — with marketing amplified through industry events (HLTH, JPM, BIO, HIMSS), content marketing, and an executive Digital Health C-Suite Series. Distribution is anchored on the company's regulatory clearance, demonstrated clinical outcomes (79% retention at 3 months and 71% at 12 months for Hizentra versus a ~45% industry average; 80%+ retention at 12 months for myVisionTrack), and the ability to compress custom builds from 12+ months to roughly 6 months.

The company is venture-backed and private, having raised $179M+ across five disclosed rounds, including a $101M Series C in March 2021 led by General Catalyst at a $750M valuation, and a $13M strategic investment in January 2026 from existing investors to accelerate AI-enabled persistence solutions. It has been recognized on the Deloitte Technology Fast 500 for two consecutive years and as a Frost & Sullivan Global Healthcare IoT Company of the Year. Customer concentration is anchored on a handful of large multi-year pharma partnerships, but the platform is configurable across eight therapeutic areas (cardiovascular, diabetes, gene therapy, immunology, mental health/neurology, oncology/hematology, rare diseases, respiratory), and the 2026 Havas Health global agency partnership signals an effort to broaden commercial reach at the brand level.

BrightInsight firmographics

Firmographics
Name
BrightInsight
Legal name
BrightInsight, Inc.
Website
https://brightinsight.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
BrightInsight provides a regulated cloud-based digital health platform for global biopharma and medtech companies, enabling compliant patient companion apps, Software as a Medical Device (SaMD) solutions, and AI-driven therapy persistence programs deployed across 60+ countries with enterprise customers including Sanofi, CSL Behring, Roche, and AstraZeneca.
Ownership category
akta.pro rank

BrightInsight industry classification

Industry
Product category
Digital Health Platform
SIC
Services-Prepackaged Software (7372), Services-Health Services (8000)
akta.pro industry
PRIMARYHLACANAH
Therapeutic Companion Apps (Drug-Device-Digital Combination)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAFAF
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLACAPAH
Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Regulated digital health platform
  • Patient persistence software
  • Biopharma digital solutions
  • Medical device software
  • SaMD platform

Where BrightInsight is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BrightInsight business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Platform/SaaS Subscription: Cloud-based platform deployed as managed service with subscription pricing. Provides infrastructure for patient companion apps, digital patient support programs, and SaMD solutions across global markets.
  2. Professional Services: Implementation, customization, and consulting services to deploy digital health solutions on the BrightInsight Platform.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise Platform Subscription

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

BrightInsight product offering

Product offering

Core offering

BrightInsight provides a cloud-based regulated digital health platform for biopharma and medtech companies, offering infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries. Its AI-enabled patient persistence solution predicts and prevents therapy drop-off by detecting behavioral signals and triggering interventions, delivering pre-built regulatory compliance modules (HIPAA, GDPR, ISO 13485, IEC 62304, HITRUST, EU MDR) and configurable tools across multiple therapeutic areas.

Product overview

BrightInsight offers a unified digital health platform architecture with multiple integrated solutions. The core BrightInsight Platform provides cloud-based infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions for biopharma and medtech companies. Built upon this platform are the Patient Persistence Solution (AI-powered therapy adherence), Disease Management Solution, and Connected Diagnostics Platform (for IVD companies). The company delivers specific patient-facing products including the MyWay App (Sanofi partnership), Hizentra App (CSL Behring), Hemgenix Companion App, and myVisionTrack App (Stanford), along with the CE-marked Emicizumab Dosing Calculator. The platform operates across 60+ countries with global regulatory compliance.

Differentiator

Problem solved

Functional benefit

Brands

  • BrightInsight Platform: The company's core regulated digital health IoT platform for biopharma and medtech companies
  • BrightInsight Ecosystem
  • Digital Disease Management Solution
  • Connected Diagnostics Platform
  • Patient Persistence Solution
  • Digital Health C-Suite Series
  • MyWay

Products and services

  • BrightInsight Platform Cloud-based regulated digital health platform for biopharma and medtech companies providing infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries.
  • Patient Persistence Solution AI-powered solution that predicts and prevents therapy drop-off by unifying patient experience, detecting behavioral signals preceding discontinuation, and triggering interventions at critical moments to keep patients on therapy longer.
  • Connected Diagnostics Platform Digital platform for in vitro diagnostics (IVD) companies that transforms device management from reactive to proactive, featuring workflow portals, analytics dashboards, proxy agent for device-to-cloud communication, and HL7/FHIR integration middleware.
  • Disease Management Solution Digital solution for biopharma and medtech companies that enhances patient experience and drives value for therapies and devices by supporting the patient journey across care settings.
  • MyWay App Software as Medical Device mobile application providing symptom tracking, medication management, and direct communication with healthcare providers for patients on Sanofi's specialty care medicines.
  • Hizentra App Patient companion app for CSL Behring supporting patients taking Hizentra with medication reminders, record management, infusion tracking, and nurse educator program access; deployed in U.S., Japan, Canada, Chile, and Argentina.
  • Patient App (Sanofi) Digital app developed with Sanofi and Regeneron supporting patients on biologic therapies, demonstrating 4% lower discontinuation rate and improved adherence after one year; adopted by more than 25,000 patients.
  • Hemgenix Companion App Companion application developed in partnership with CSL for Hemgenix gene therapy to support patients undergoing treatment.
  • Emicizumab Dosing Calculator CE-marked dosing calculator for Emicizumab, a regulated digital health solution built on the BrightInsight Platform.
  • myVisionTrack App Mobile application for macular disease patients developed with Stanford Health Care, showing 80%+ patient retention at 12 months with 83% registered retinal patient engagement.
  • Data & Insights Solution Solution component providing real-world data capture and actionable insights to help biopharma companies improve patient care and drive measurable business value.
  • Software as a Medical Device (SaMD) Solutions Comprehensive offering for developing, launching, and scaling Software as a Medical Device products including algorithms and clinical decision support tools.

Quantifiable outcome

  • 4% lower discontinuation rate and 4% improvement in adherence after one year for Sanofi Patient App users vs. non-users
  • +5 more outcomes

Companies that use BrightInsight

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles3 records

BrightInsight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

BrightInsight partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship and core.

  • Havas HealthflagshipGTM or Marketing Partner · 26 February 2026Exclusive global strategic partnership designating Havas Health as BrightInsight's single global agency partner for digital patient persistence and adherence solutions. Merges Havas Health's healthcare strategy and patient journey expertise with BrightInsight's compliant digital health platform. Addresses estimated $500B+ annual cost of poor patient adherence.
  • SanofiflagshipStrategic or Co-development Partner · 17 December 2024Expanded multi-year partnership (initial 2022) to develop companion applications for Sanofi's specialty care medicines including MyWay mobile app and Patient App for biologic therapies. Demonstrated 4% reduction in discontinuation and 4% adherence improvement. Expansion across international markets and specialty care portfolio.
  • Google CloudcoreTechnology or Integration · 7 May 2024Expanded partnership to enhance patient journey through generative AI. Long-standing technology partner since 2018 launch on Google Cloud Platform. 2018 and 2019 Google Cloud Partner of the Year for Healthcare and Life Sciences.
  • bioMérieuxcoreStrategic or Co-development Partner · 21 September 2022Partnership to launch clinical digital solutions for diagnostics. Connected Diagnostics Platform for clinical decision support.
  • UCBcoreStrategic or Co-development Partner · 8 March 2022Partnership to build digital care solutions for rare diseases leveraging BrightInsight Platform for compliant digital health solutions.
  • AstraZenecacoreStrategic or Co-development Partner · 25 March 2020Global digital health partnership for chronic disease management. BrightInsight IoT platform selected to build and manage digital health solutions within regulatory-compliant environment.
  • Novo NordiskcoreStrategic or Co-development Partner · 23 October 2018Connected insulin pens and digital diabetes management solutions using BrightInsight Platform. Long-standing partnership dating to Flex-era origins.
  • RegeneronflagshipStrategic or Co-development PartnerCollaboration with Sanofi on Patient App for key biologic therapy. BrightInsight developed the digital solution supporting patients on therapy with measurable adherence and persistence outcomes.
  • CSL BehringflagshipStrategic or Co-development PartnerEnterprise agreement for digital health solutions across brand portfolio. Hizentra app with 25%+ adoption rate, 79% retention at 3 months. Global expansion to Latin America and Canada. Hemgenix companion app for gene therapy.
  • RochecoreStrategic or Co-development PartnerDigital health initiatives within Roche Personalized Healthcare Division.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

BrightInsight competitors and assessment

Company assessment

Broad incumbents

  • Salesforce Health Cloud: Salesforce Health Cloud is a broad CRM/patient engagement platform that biopharma and medtech customers can use for patient companion apps; a broader incumbent that competes for the same enterprise buyer.
  • IQVIA: IQVIA's eCOA, Patient Cloud and decentralized trial offerings target the same biopharma/medtech buyers with regulated patient-engagement and data-capture software, but as part of a much larger CRO and analytics portfolio.
  • Medidata (Dassault Systèmes): Medidata's Rave eCOA and decentralized clinical trial platform address pharma patient engagement and SaMD-adjacent use cases; competes for the same enterprise budget lines at top biopharma.

Direct peers

  • Veeva Systems: Veeva Vault is the dominant regulated SaaS platform for life sciences, including patient engagement and clinical operations. Veeva is the most direct functional comparable to BrightInsight's regulated platform model serving biopharma.
  • Medable: Medable provides a regulated, decentralized clinical trial and eCOA platform for biopharma — direct overlap with BrightInsight's SaMD and patient companion app capabilities for clinical and commercial use.
  • Science 37: Science 37 operates a decentralized clinical trial platform with connected patient apps and remote data capture, competing for the same biopharma digital engagement and SaMD deployments.

Emerging players

  • Castor: Castor offers a regulated eClinical and connected device data platform for clinical trials — overlapping with BrightInsight's Connected Diagnostics and SaMD modules but at smaller scale and primarily trial-focused.
  • ObvioHealth: ObvioHealth provides a decentralized trial and patient engagement app platform aimed at biopharma sponsors, with partial overlap on patient companion apps and adherence.

Others

  • Datavant: Datavant focuses on health-data connectivity and real-world data — adjacent to BrightInsight's Data & Insights module — and could be a partner or competitor in the biopharma RWE layer.
  • Redox: Redox provides healthcare interoperability APIs; BrightInsight already integrates with HL7/FHIR and partners with Redox-style vendors, making it a comparable ecosystem/data-exchange peer.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BrightInsight social profiles

Digital presence

BrightInsight compliance and trust

Trust signal

Compliance12 records

BrightInsight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrightInsight leadership team

Management profile

Number of profiles

Profiles8 records

BrightInsight funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrightInsight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrightInsight

What does BrightInsight do?

BrightInsight provides a cloud-based regulated digital health platform for biopharma and medtech companies, offering infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries. Its AI-enabled patient persistence solution predicts and prevents therapy drop-off by detecting behavioral signals and triggering interventions, delivering pre-built regulatory compliance modules (HIPAA, GDPR, ISO 13485, IEC 62304, HITRUST, EU MDR) and configurable tools across multiple therapeutic areas.

Is BrightInsight a public or private company?

BrightInsight is a private company. It is classified as venture growth investor backed and is currently operating.

When was BrightInsight founded?

BrightInsight was founded in 2018. It employs 101 to 250 people.

Where is BrightInsight based?

BrightInsight is headquartered in San Jose, United States, in the North America region.

How does BrightInsight make money?

Two revenue lines are on record. Platform/SaaS Subscription is the primary driver. The others are professional Services.

Who are BrightInsight's main competitors?

Broad incumbents on record are Salesforce Health Cloud, IQVIA and Medidata (Dassault Systèmes). Direct peers are Veeva Systems, Medable and Science 37. Emerging players are Castor and ObvioHealth. Others are Datavant and Redox.

Does BrightInsight have an API?

No public API is recorded for BrightInsight.

What industry is BrightInsight in?

BrightInsight's product category is Digital Health Platform. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs). Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumAstraZeneca’s digital health alliance with BrightInsight bears fruitAstraZeneca has launched the AMAZE Disease Management Platform, a digital health toolkit developed in partnership with BrightInsight to support patients with chronic conditions. The mobile app and clinician dashboard integrate with electronic health records in the US to improve patient engagement and therapy adherence. AstraZeneca plans to expand the platform to new therapeutic areas and regions in 2021.PR NewswireHavas Health and BrightInsight Forge Exclusive Alliance to Tackle Pharma's $500B+ Patient ProblemHavas Health announced an exclusive global strategic partnership with BrightInsight, designating Havas Health as BrightInsight's single global agency partner to deliver digital patient persistence and adherence solutions for the pharmaceutical industry. The collaboration merges Havas Health's healthcare strategy and patient journey expertise with BrightInsight's AI-enabled, compliant digital health platform, which has demonstrated the ability to reduce long-term therapy discontinuation by four percentage points and increase adherence by four percentage points compared to traditional patient support programs. The partnership aims to address the estimated $500 billion annual cost of poor patient adherence to prescribed therapies, with coverage spanning 60-plus countries where Havas Health operates.HIT ConsultantHavas Health and BrightInsight Form Global Digital Health Partnership for BiopharmaHavas Health announced a strategic global partnership with BrightInsight to provide digital health solutions for biopharma, focusing on improving patient adherence to therapies. BrightInsight's platform, which operates in over 60 countries, aims to reduce therapy discontinuation and enhance patient support programs. This partnership represents a shift towards active disease management with a regulatory-compliant digital infrastructure.LBBOnlineHavas Health Expands into Digital Health Infrastructure with BrightInsight PartnershipHavas Health formed a strategic partnership with BrightInsight to offer digital health solutions that improve patient adherence and support, targeting the chronic illness market globally. The collaboration leverages BrightInsight’s compliant, AI-enabled platform to enhance real-world effectiveness of therapies and reduce therapy discontinuation.Pulse 2.0BrightInsight: $13 Million Closed To Expand AI-Enabled Medication Adherence PlatformBrightInsight, a San Jose-based digital health company, has closed a $13 million funding round to accelerate development of its AI-enabled medication adherence platform and scale patient support programs globally for biopharma clients.GlobeNewswireBrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and InnovationBrightInsight announced the appointment of three industry veterans to its Executive Leadership Team, including Robert Zdon as COO, Eric Redline as SVP of Market Development and Customer Success, and Leigh Wager as VP of Product. These strategic hires follow a year of significant milestones for the company, such as successful global launches and a new round of fundraising. The expansion underscores BrightInsight’s commitment to scaling operations and defining digital health infrastructure for biopharma partners.GlobeNewswireBrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence SolutionsBrightInsight announced a $13 million investment round from existing and new investors to accelerate its AI-enabled medication persistence and adherence solutions. The capital will scale programs like the Patient App with Sanofi and Regeneron, addressing non-adherence that causes up to 25% of U.S. hospitalizations and $100-300 billion in annual costs.YahooBrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence SolutionsBrightInsight, a digital health solutions company, announced a $13 million strategic investment round from investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners on January 20, 2026. The funding will accelerate development of AI-enabled medication persistence and adherence solutions and support scalability of programs like the Patient App from its collaboration with Sanofi and Regeneron. The company reported participation rates of 30-70% among invited patients in deployed programs, with similar retention one year later across various disease areas.GlobeNewswireBrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence SolutionsBrightInsight, a digital health solutions company headquartered in San Jose, announced a $13 million investment round from existing and new investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. The funding will accelerate development of AI-enabled medication persistence and adherence solutions and enable scalability of programs such as the Patient App from its collaboration with Sanofi and Regeneron. The company cited that adherence rates for chronic diseases hover at approximately 50%, contributing to roughly 125,000 preventable deaths annually and generating $100 billion to $300 billion in avoidable healthcare expenses each year in the United States.FinSMEsBrightInsight Raises $13M in FundingBrightInsight, a San Jose-based digital health solutions provider, raised $13M in funding from investors including Eclipse, General Catalyst, Insight Partners, Mayo Clinic, and New Leaf Venture Partners. The company plans to use the funds to accelerate development of its AI-enabled medication persistence and adherence solutions and expand programs such as the Patient App developed through its collaboration with Sanofi and Regeneron. The platform serves biopharma companies by providing cloud-based infrastructure for patient companion apps, digital patient support programs, and software-as-a-medical-device solutions.